Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases? Por C Beyer, O Distler, JH Distler

Obter o texto integral

FGF2 overrides key pro-fibrotic features of bone marrow stromal cells isolated from Modic type 1 change patients Por I Heggli, U Blache, N Herger, T Mengis, PK Jaeger, R Schuepbach, N Farshad-Amacker, F Brunner, JG Snedeker, M Farshad, O Distler, S Dudli

Obter o texto integral

Low back pain patients with Modic type 1 changes exhibit distinct bacterial and non-bacterial subtypes Por I. Heggli, T. Mengis, C.J. Laux, L. Opitz, N. Herger, D. Menghini, R. Schuepbach, N.A. Farshad-Amacker, F. Brunner, A.J. Fields, M. Farshad, O. Distler, S. Dudli

Obter o texto integral

Pro-fibrotic phenotype of bone marrow stromal cells in Modic type 1 changes Por I Heggli, S Epprecht, A Juengel, R Schuepbach, N Farshad-Amacker, C German, T Mengis, N Herger, L Straumann, S Baumgartner, M Betz, JM Spirig, F Wanivenhaus, N Ulrich, D Bellut, F Brunner, M Farshad, O Distler, S Dudli

Obter o texto integral